Literature DB >> 17171682

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Luigia Lombardi1, Giulia Poretti, Michela Mattioli, Sonia Fabris, Luca Agnelli, Silvio Bicciato, Ivo Kwee, Andrea Rinaldi, Domenica Ronchetti, Donata Verdelli, Giorgio Lambertenghi-Deliliers, Francesco Bertoni, Antonino Neri.   

Abstract

To investigate the patterns of genetic lesions in a panel of 23 human multiple myeloma cell lines (HMCLs), we made a genomic integrative analysis involving FISH, and both gene expression and genome-wide profiling approaches. The expression profiles of the genes targeted by the main IGH translocations showed that the WHSC1/MMSET gene involved in t(4;14)(p16;q32) was expressed at different levels in all of the HMCLs, and that the expression of the MAF gene was not restricted to the HMCLs carrying t(14;16)(q32;q23). Supervised analyses identified a limited number of genes specifically associated with t(4;14) and involved in different biological processes. The signature related to MAF/MAFB expression included the known MAF target genes CCND2 and ITGB7, as well as genes controlling cell shape and cell adhesion. Genome-wide DNA profiling allowed the identification of a gain on chromosome arm 1q in 88% of the analyzed cell lines, together with recurrent gains on 8q, 18q, 7q, and 20q; the most frequent deletions affected 1p, 13q, 17p, and 14q; and almost all of the cell lines presented LOH on chromosome 13. Two hundred and twenty-two genes were found to be simultaneously overexpressed and amplified in our panel, including the BCL2 locus at 18q21.33. Our data further support the evidence of the genomic complexity of multiple myeloma and reinforce the role of an integrated genomic approach in improving our understanding of the molecular pathogenesis of the disease. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat. Copyright (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17171682     DOI: 10.1002/gcc.20404

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  29 in total

1.  Pathway-based identification of SNPs predictive of survival.

Authors:  Herbert Pang; Michael Hauser; Stéphane Minvielle
Journal:  Eur J Hum Genet       Date:  2011-02-02       Impact factor: 4.246

2.  Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.

Authors:  Chee Man Cheong; Krzysztof M Mrozik; Duncan R Hewett; Elyse Bell; Vasilios Panagopoulos; Jacqueline E Noll; Jonathan D Licht; Stan Gronthos; Andrew C W Zannettino; Kate Vandyke
Journal:  Cancer Lett       Date:  2020-01-31       Impact factor: 8.679

3.  Anti-CD138-targeted interferon is a potent therapeutic against multiple myeloma.

Authors:  Esther M Yoo; Kham R Trinh; Danh Tran; Alex Vasuthasawat; Juan Zhang; Bao Hoang; Alan Lichtenstein; Sherie L Morrison
Journal:  J Interferon Cytokine Res       Date:  2014-10-29       Impact factor: 2.607

4.  Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.

Authors:  Yoichi Imai; Eri Ohta; Shu Takeda; Satoko Sunamura; Mariko Ishibashi; Hideto Tamura; Yan-Hua Wang; Atsuko Deguchi; Junji Tanaka; Yoshiro Maru; Toshiko Motoji
Journal:  JCI Insight       Date:  2016-04-21

5.  Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.

Authors:  Sridurga Mithraprabhu; Anna Kalff; Annie Chow; Tiffany Khong; Andrew Spencer
Journal:  Epigenetics       Date:  2014-11       Impact factor: 4.528

6.  Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Authors:  Holly A F Stessman; Linda B Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A Walsh; John J Sunderland; Nathan G Dolloff; Michael A Linden; Fenghuang Zhan; Siegfried Janz; Chad L Myers; Brian G Van Ness
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

7.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

8.  Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.

Authors:  A Gilchrist; T D Gauntner; A Fazzini; K M Alley; D S Pyen; J Ahn; S J Ha; A Willett; S E Sansom; J L Yarfi; K A Bachovchin; M R Mazzoni; J R Merritt
Journal:  Br J Pharmacol       Date:  2014-11       Impact factor: 8.739

9.  TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.

Authors:  John K Simmons; Jyoti Patel; Aleksandra Michalowski; Shuling Zhang; Bih-Rong Wei; Patrick Sullivan; Ben Gamache; Kenneth Felsenstein; W Michael Kuehl; R Mark Simpson; Adriana Zingone; Ola Landgren; Beverly A Mock
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

10.  FOXM1 is a therapeutic target for high-risk multiple myeloma.

Authors:  C Gu; Y Yang; R Sompallae; H Xu; V S Tompkins; C Holman; D Hose; H Goldschmidt; G Tricot; F Zhan; S Janz
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.